Erik Moedt - Publications

Relationship Between hsCRP, Glycaemic Control and Response to Sotagliflozin in Type 1 Diabetes: A Post Hoc Analysis of the inTandem3 Trial.

Journal: Diabetes, obesity & metabolism

Published: April 14, 2026

Intra-Individual Variability of Urinary EGF and Clusterin, and Effect of Frozen Storage on Stability: Results from UVALID.

Journal: International journal of molecular sciences

Published: March 25, 2026

Novel protein biomarkers for risk stratification and personalized medicine.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: January 28, 2026

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial.

Journal: Diabetes, obesity & metabolism

Published: December 21, 2025

Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition.

Journal: Journal of the American Society of Nephrology : JASN

Published: November 18, 2025

Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE Trials.

Journal: Diabetes care

Published: July 24, 2025

Urinary clusterin as a biomarker of human kidney disease progression and response to the endothelin receptor antagonist atrasentan: An exploratory analysis from the SONAR trial.

Journal: Nature communications

Published: February 28, 2025

Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: July 01, 2024